Diagnostic Center | March 23, 2024
AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Combination shows consistent benefit across prespecified post-progression outcomes
Combination shows consistent benefit across prespecified post-progression outcomes
Subscribe To Our Newsletter & Stay Updated